Little is known about the roles of b-arrestins in the regulation of brain CB 1 cannabinoid receptors. This study investigated the role of b-arrestin2 in cannabinoid behavioral effects using b-arrestin2 -/ -mice and their wild-type counterparts. A variety of cannabinoid ligands from different chemical classes that exhibit a variety of efficacies for activation of CB 1 receptors were investigated, including D 9 -tetrahydrocannabinol, CP55940, methanandamide, JWH-073, and O-1812. D 9 -tetrahydrocannabinol produced both greater antinociception and greater decreases in body temperature in b-arrestin2 -/ -compared with b-arrestin2 + / + mice. No significant differences were, however, present in either assay for the other CB 1 agonists. Antagonist radioligand binding indicated no difference in the density of cannabinoid CB 1 receptors in the cerebellum, cortex, or hippocampus of b-arrestin2 + / + and -/ -mice. These data demonstrate that b-arrestin2 may regulate cannabinoid CB 1 receptor sensitivity in an agonist-specific manner.
Introduction
Cannabinoid CB 1 receptors seem to mediate the majority of the central nervous system actions of cannabinoid compounds . CB 1 are Gprotein coupled receptors (GPCRs) and couple primarily to the G ai and/or G ao subtypes Prather et al., 2000) . Cannabinoid agonists acting through CB 1 receptors elicit catalepsy, analgesia, decreases in spontaneous activity and body temperature (Adams and Martin, 1996) , and disruption of memory (Heyser et al., 1993) .
Four subtypes of arrestins and seven subtypes of G-protein coupled receptor kinases (GRKs) have been cloned. Arrestin1 and 4 and GRK1 and 7 are visual subtypes and regulate photoreceptor molecules (rhodopsin). Arrestin2 and 3 (also known, respectively as b-arrestin1 and 2) and GRK2, 3, 5, and 6 are distributed widely, and are believed to regulate a variety of GPCRs (Luttrell and Lefkowitz, 2002) . Some evidence that each subtype of GRK phosphorylates a subset of GPCRs is present, and that each subtype of arrestin binds a subset of GPCRs. Alternatively, it may be that each of the two b-arrestins binds the same GPCRs but exerts different effects upon the receptor. The role of specific subtypes of arrestin and/or GRK has been assessed for only a few GPCRs. Some evidence for which subtypes of GRK and arrestin modulate cannabinoid receptors was provided by cotransfection of CB 1 , b-arrestin2, and GRK3 into oocytes. These studies indicated that b-arrestin2 and GRK3 could induce desensitization of CB 1 (Jin et al., 1999) . A second study involving cannabinoid receptors indicated that expression of dominant-negative forms of GRK2 and b-arrestin inhibited the desensitization of the response to cannabinoid ligands in cultured hippocampal neurons (Kouznetsova et al., 2002) .
Much of the work to match specific GPCRs with b-arrestin and GRK subtypes has been accomplished in transfected cell lines, where it has been noted that overexpression of these proteins may lead to nonselective or irrelevant interactions . Thus, the activity of specific subtypes in the regulation of specific GPCRs remains largely undetermined. Mouse brain naturally expresses each of these proteins, therefore comparison of wild-type and transgenic b-arrestin2 knockout mice represents a strategy that provides results that may be more physiologically relevant. Earlier studies have shown that b-arrestin2 -/mice were more sensitive to the acute effects of the m-opioid agonist morphine , and exhibited attenuated tolerance to chronic morphine (Bohn et al., 2002) . Interestingly, a morphine treatment that failed to produce significant tolerance still resulted in morphine dependence in these animals (Bohn et al., 2000) , but morphine did not show enhanced side effects (Raehal et al., 2005) . Other investigators have found that GRK5 -/mice exhibited supersensitivity and impaired densensitization to muscarinic agonists .
This study compared the acute effects of several cannabinoid receptor agonists in b-arrestin2 + / + and -/mice to examine the effect of b-arrestin2 deletion on the efficacy of cannabinoids in whole mice. The classification of each compound in this study as a full or partial agonist is based on its ability to activate G-proteins via CB 1 receptors in brain membranes as determined by
binding. The ED 50 values reported here are earlier published reports of in-vivo activity for the latency to tail withdrawal from a hot water bath (tail flick test of antinociception) and depression of rectal temperature in mice. As the values for the two assays were quite similar, the average of the reported values for each compound is given below. CP55940 is a widely-used full agonist (Breivogel et al., 2001) , and exhibits ED 50 values around 0.1 mg/kg (Fan et al., 1994) . D 9 -tetrahydrocannabinol (THC) is the primary physiologically active cannabinoid agonist found in Cannabis sativa. In contrast with CP55940, THC is a weak partial agonist (Sim et al., 1996; Burkey et al., 1997; and exhibits ED 50 values around 1 mg/kg (Fan et al., 1994; Wiley et al., 1998) . Methanandamide is a metabolically stable analog of the endogenous cannabinoid, anandamide, that exhibits high efficacy and is classified as a full agonist or high-efficacy partial agonist Breivogel and Childers, 2000) . Methanandamide has reported ED 50 values around 20 mg/kg (Adams et al., 1995) . O-1812 is another analog of the endogenous cannabinoid, anandamide, which exhibits efficacy for G-protein activation similar to THC (Breivogel et al., 2001) with ED 50 values around 0.03 mg/kg . JWH-073 is an aminoalkylindole cannabinoid agonist with ED 50 values around 2 mg/kg (Wiley et al., 1998) . The efficacy of each agonist for activation of G-proteins in brain membranes is confirmed in this study.
Methods

Subjects
C57BL/6 b-arrestin2 knockout and littermate wild-type mice were generously supplied by the laboratory of Dr Robert Lefkowitz of Duke University (Durham, North Carolina, USA) and were bred in the animal facility of Campbell University School of Pharmacy. At Campbell University, homozygous wild-type were bred with homozygous wild-type and homozygous knockouts were bred with homozygous knockouts, obviating genotyping of the offspring. It has been reported that results from similar types of experiments using the same strain of b-arrestin2 -/mice bred in this manner did not differ from those obtained in mice bred from heterozygous breeders (Raehal et al., 2005) . All experiments were conducted in accordance with NIH guidelines for the care and use of laboratory animals and with an approved animal protocol from the Campbell University Animal Care and Use Committee.
In-vivo assays
Drugs or vehicle (1 : 1 : 18 emulphor : ethanol : double distilled H 2 O) were administered by intraperitoneal (i.p.) injection at 0.01 ml/g of body weight. As the agonists, O-1812 and JWH-073 being available in limited supply and the knockout mice being similarly limited in number, concentrations of each agonist were selected based on the ED 50 values in the tail immersion and rectal temperature tests. Each drug was administered at a dose 10-26 times higher than the earlier determined ED 50 values (Table 1) . These higher doses were chosen because in the earlier studies the drugs were administered intravenously, whereas they were given i.p. in this study. Additionally, the earlier studies used a 10 s cut-off time for the tail immersion test, whereas this study utilized a 30 s cut-off to give a greater range of possible values and greater sensitivity to detect differences among groups of animals. O-1812 was used in this study at a higher dose compared with its earlier reported ED 50 , as an initial test assay using 0.1 mg/kg produced very little effect.
Latency to tail withdrawal as a measurement of antinociceptive activity
This method was similar to that described earlier (Winters et al., 1988) . In initial experiments, mice were held and the tip of the tail was immersed in a water bath with the temperature set to 501C, 531C, or 561C. When the tail was flicked from the water or after 30 s (cut-off time) elapsed, the time in the water was recorded and the mouse returned to its cage. In subsequent studies, The 'Earlier ED 50 ' values are those reported for the latency to tail withdrawal test and hypothermia in mice, respectively, though some were converted from other units (e.g. mmol/kg) to mg/kg. 'Current dose' is that used in this study and the 'Approximate ratio' is the current dose divided by the average of the earlier ED 50 values.
latency was measured once before (basal latency), and at several times after (test latency), an i.p. injection of drug or vehicle. For this test and the hot plate test (see below), data were expressed as a percentage of the maximum possible effect (%MPE) = (test latency-basal latency)/(cut-off time-basal latency) Â 100% for each animal (Dewey et al. 1970) . Mean and SEM for latency to tail withdrawal (in seconds) and %MPE were calculated for each group of 5-9 mice.
Hot plate measurement of antinociceptive activity
Mice were placed under a large beaker on a digitally controlled Thermolyne Mirak (Dubuque, Iowa, USA) hot plate with the temperature set to 561C once before and at several times after an i.p. injection of drug or vehicle. When the mouse licked a rear paw, jumped, or the 60-s cut-off time elapsed, the mouse was removed immediately from the plate and the time on the plate was recorded. %MPE was calculated as above.
Rectal temperature
Rectal temperature was determined to a tenth of a degree by a thermistor probe attached to a traceable digital thermometer from Control Company (Friendswood, Texas, USA), lubricated with glycerin and inserted 2 cm. Temperature was recorded before and at various times after i.p. injection of drug or vehicle. For each animal, the change in rectal temperature is determined as final minus predrug temperature and the data expressed as mean change in rectal temperature for each group. Brain regions were dissected from whole brains on ice and homogenized in cold membrane buffer (50 mmol/l Tris-HCl pH 7.4, 3 mmol/l MgCl 2 , 0.2 mmol/l EGTA) and then centrifuged at 48 000g for 10 min at 41C. Pellets were resuspended in membrane buffer by homogenization, and then centrifuged again at 48 000g for 10 min at 41C. Pellets from the second centrifugation were homogenized in membrane buffer, divided into cryovials and stored at -801C until use.
[ 35 S]guanosine-5 0 -O-3-thiotriphosphate binding to brain membranes
On the day of assay membranes were thawed, resuspended in membrane buffer containing 100 mmol/l NaCl using a polytron and preincubated for 10 min at 301C in 0.004 units/ml adenosine deaminase (240 units/mg protein, Sigma Chemical Co., St. Louis, Missouri, USA) to remove endogenous adenosine. Membranes were assayed for protein content (Bradford, 1976 ) before addition to assay tubes. Assay tubes contained membrane homogenate with 10-20 mg of protein, membrane buffer with 100 mmol/l NaCl, 0.1 nmol/l [ 35 S]GTPgS, 30 mmol/l GDP, 1 mg/ml (w/v) bovine serum albumin (BSA) and various concentration of each agonist. Assays were incubated for 1 h, and nonspecific binding was determined in the presence of 30 mmol/l unlabelled GTPgS. Each assay was terminated by filtration under vacuum through Whatman GF/B glass fiber filters, after three washes with cold Tris-HCl buffer, pH 7.4. Bound radioactivity was determined by liquid scintillation spectrophotometry at 95% efficiency for [ 35 S] after overnight extraction of the filters in 3.5 ml ScintiSafe Econo 1 scintillation fluid (Fisher Scientific, Pittsburgh, Pennsylvania, USA).
[ 3 H]SR141716A receptor binding to brain membranes
On the day of assay membranes were thawed, resuspended in assay buffer with 100 mmol/l NaCl using a polytron and assayed for protein content (Bradford, 1976) . Membrane homogenate containing 16 mg of membrane protein was added to assay tubes containing assay buffer, 1 mg/ml (w/v) BSA, and [ 3 H]SR141716A. Assays were incubated for 1 h; nonspecific binding was determined in the presence of 5 mmol/l unlabelled SR141716A. Each assay was terminated by filtration under vacuum through Whatman GF/B glass fiber filters that had been soaked in cold Tris-HCl buffer, pH 7.4 with 5 mg/ml BSA, followed by seven washes with cold Tris-HCl buffer, pH 7.4 with 0.5 mg/ml BSA. Bound radioactivity was determined by liquid scintillation spectrophotometry at about 42% efficiency for [ 3 H] after overnight extraction of the filters in 3.5 ml ScintiSafe Econo 1 scintillation fluid (Fisher Scientific). 
Data analysis
Significant effects of drugs were determined by two-way analysis of variance (ANOVA) comparing the effect of each drug versus vehicle at each time after injection (time vs. treatment) at P value of less than 0.05 using Prism (GraphPad Software, San Diego, California). Significant differences between the effects of each drug treatment in b-arrestin2 + / + and -/mice were determined by two-way ANOVA (time vs. genotype) at P value of less than 0.05, followed by Bonferroni's posttest (at P < 0.05) using Prism, to determine at which time points b-arrestin2 + / + and -/mice exhibited differences in response. In the text of the Results section, P values are those for two-way ANOVAs. In the figures and legends, P values for differences between the genotypes at specific time points are from Bonferroni's posttest, unless otherwise specified. All data are mean ± SEM of experiments carried out with 5-9 mice per treatment group. 
Results
Behavioral effects of cannabinoids in beta-arrestin2 + / + and -/ -mice Mice were tested for latency to tail withdrawal from a water bath set to different temperatures ( Fig. 1) . b-arrestin2 -/mice exhibited greater latencies to withdraw (two-way ANOVA for temperature vs. genotype, P < 0.020) than b-arrestin2 + / + mice (7.0 ± 1.4 s vs. 14.9 ± 3.0 s), at the lowest temperature tested of 501C (P < 0.001 by Bonferroni's posttest). This difference was not present at the higher temperatures of 531C and 561C, where the latencies for both genotypes were approximately 2.5 and 1.5 s, respectively. Therefore, all experiments in which the effects of cannabinoid drugs were tested were carried out using a water bath temperature of 531C to achieve a basal latency around 2.5 s, and to avoid the complication of differences in basal latency across genotypes.
The vehicle used to dissolve each agonist for whole animal assays, 1 : 1 : 18 ethanol : emulphor : water, was evaluated in the tail withdrawal and rectal temperature assays using the same protocol as were used for each agonist (Fig. 2, right panels) . Results for the tail withdrawal test indicated that vehicle did not produce significant effects in either genotype compared with preinjection responses (one-way ANOVA, P > 0.10), and there were no differences between the genotypes as assessed by two-way ANOVA for genotype versus time (P = 0.87). Vehicle did produce small decreases in rectal temperature compared with preinjection values in b-arrestin2 + / + mice from 60-360 min (one-way ANOVA, P < 0.001 followed by Dunnett's test) and b-arrestin2 -/mice from 60-240 min (P < 0.001) postinjection. No differences were, however, observed between the genotypes in the rectal temperature response to vehicle (twoway ANOVA, P = 0.52). As there was a small effect of vehicle on rectal temperature in these mice, all effects of drugs in these assays were compared with the response of the same genotype to vehicle by two-way ANOVA for time versus treatment (drug or vehicle).
Tests of the response to the full agonist, CP55940, were conducted at 1.0 and 0.3 mg/kg (Fig. 2, left panels) . At 1.0 mg/kg, CP55940 increased the latency to tail withdrawal to the cut-off time of 30 s in some mice from both groups at 30 min after injection, and the antinociceptive Cannabinoids in beta-arrestin2 -/ -mice Breivogel et al. 301 effects lasted for at least 4 h (Fig. 2, top left panel) . At the same time as the tail withdrawal test, rectal temperature measurements in the same mice showed mean decreases in body temperature of around 71C that lasted between 1 and 4 h after injection (Fig. 2, bottom left panel) . At 0.3 mg/kg, the effects of CP55940 were lesser in magnitude; 8-13% of the MPE in the tail withdrawal test (Fig. 2, top left panel) and a 41C drop in body temperature (Fig. 2, bottom left panel) . It was observed that CP55940 at both doses affected antinociception and decreased the body temperature of the mice, determined by two-way ANOVA at P value of less than 0.05 for time versus treatment comparing CP55940 with vehicle (the effects of vehicle are shown in Fig. 2 , right panels). In contrast, there were no differences between the b-arrestin2 + / + and -/mice in the magnitude of the effects at any time at either dose (twoway ANOVA P > 0.05 for each assay comparing time vs. genotype).
In experiments with THC (Fig. 2, top right panel) , 10 mg/kg produced significantly greater effects than vehicle in the tail withdrawal test between 1 and 2.5 h in b-arrestin2 + / + mice (P < 0.001). In b-arrestin2 -/mice the effect was greater than vehicle beginning at 1 h and continuing for at least 8 h postinjection (P < 0.001). Both b-arrestin2 + / + and -/mice experienced greater rectal temperature decreases after THC than vehicle beginning at 30 min and continuing for at least 8 h. Although the + / + mice had a maximum decrease of 4.41C, the -/mice had a decrease of 6.01C at the same time point (Fig. 2, bottom right panel) . In contrast with the effects of CP55940, the differences between b-arrestin2 + / + and -/mice were determined to be statistically significant by two-way ANOVA (P < 0.05 and 0.02), for antinociception and temperature depression, respectively. The time points at which the two genotypes exhibited significant differences were determined by Bonferroni's posttest (shown in Fig. 2) . Effects of CP55940 and D 9 -tetrahydrocannabinol (THC) in b-arrestin2 + / + and -/ -mice. Mice were assayed before and at different times after intraperitoneal injection of either 1.0 or 0.3 mg/kg CP55940 (left) or 10 mg/kg THC or vehicle (right) for latency to tail withdrawal (above) and rectal temperature (below). Change in rectal temperature and %maximum possible effect (%MPE) were calculated as described under Methods section. Data shown are mean ± SEM with n = 5 for each genotype for CP55940; n = 6-9 for THC, and n = 6 for vehicle. *P < 0.05, **P < 0.01, ***P < 0.001, at the times marked, for b-arrestin2 + / + versus -/ -by Bonferroni's posttest.
One additional full agonist (methanandamide) and two additional partial agonists (O-1812 and JWH-073) for the cannabinoid receptor were also assayed. The identification of the relative efficacies of all five compounds were determined earlier (see introduction), and confirmed by our laboratory using agonist-stimulated [ 35 S]GTPgS binding in wild-type mouse cerebellar membranes (see Table 2 and below for results).
In the in-vivo assays, 50 mg/kg methanandamide produced only 10% MPE in the tail withdrawal assay (Fig. 3 , left top panel) and a rectal temperature decrease of only 21C (Fig. 3, bottom left panel) in both b-arrestin2 + / + and -/mice. Drug effects were determined to be statistically significant compared with the effects of vehicle (P < 0.05 at each dose for each genotype in each assay), but did not differ between b-arrestin2 + / + and -/mice. As the effects of 50 mg/kg methanandamide were minimal, a higher dose of 250 mg/kg was assayed. The higher dose produced 60-100% MPE in the tail withdrawal assay (Fig. 3, top left panel) and a rectal temperature decreases of 6.5-81C (Fig. 3, bottom left  panel) , but there were still no significant differences between b-arrestin2 + / + and -/mice (P = 0.85 and P = 0.18, respectively). For this treatment, the difference in the mean responses of the wild-type and b-arrestin2 -/mice did seem to be more different than the responses to the other treatments that were not significantly different. Closer inspection of the data from the individual mice reveals that one-third of the mice in the wild-type group showed almost no increase in latency to tail withdrawal and relatively small changes in temperature, whereas the other two-thirds of the wild-type mice showed responses to 250 mg/kg methanandamide that were greater in magnitude and were indistinguishable from the responses of the b-arrestin2 -/mice. In assays with THC, the differences were clearly not attributable to a minority of mice failing to show a significant response to drug treatment as was seen with methanandamide. Two-thirds of the + / + mice treated with THC had lower increases in latency to tail withdrawal and decreases in temperature than any of the -/mice. The remaining one-third of + / + mice had responses that were similar to those of the -/mice, but at most time points, the + / + mice were similar only to those -/mice that showed the smallest responses.
O-1812 at 2.5 mg/kg produced no significant effects on latency to tail withdrawal (Fig. 3 , top right panel) in either b-arrestin2 + / + (P = 0.66) or -/mice (P = 0.66). O-1812 did, however, produce significant decreases in rectal temperature (Fig. 3 , bottom right panel) from 2.5-6 h in + / + mice (P < 0.001) and from 4-6 h in -/mice (P < 0.001). O-1812 exerted maximal effects in both genotypes from 2.5-6 h. JWH-073 at 20 mg/kg produced significant antinociception compared with vehicle in both b-arrestin2 + / + (P < 0.02) and -/ -(P < 0.01) mice from 30-60 min (Fig. 3, top right panel). Rectal temperature (Fig. 3, bottom right panel) was decreased greater than the effect of vehicle beginning at 30 min and remained so through 4 h in both genotypes (P < 0.001). As with CP55940, the effects of methanandamide, O-1812 and JWH-073 were not different between b-arrestin2 + / + and -/mice.
To confirm that deletion of b-arrestin2 selectively increases the efficacy of THC but not CP55940, a second assay of antinociception, the hot plate test, was carried out using 1.0 mg/kg CP55940, 10 mg/kg THC or vehicle. At this temperature, there was no difference in predrug latencies between the b-arrestin2 + / + (18.0 ± 3.0 s) and -/ -(17.7 ± 3.6 s) mice. Vehicle did not produce any significant effects compared with preinjection responses in either genotype (one-way ANOVA, P = 0.93 in b-arrestin + / + and P = 0.954 in -/mice), and response to vehicle did not differ between + / + and -/mice (two-way ANOVA, P = 0.971). CP55940 produced 80-100% MPE in each genotype from the first time point of 15 min through the last at 2 h postinjection, which was significantly greater (two-way ANOVA, P < 0.05) than the effect of vehicle at every time (Fig. 4, left panel) . As before, CP55940 did not exhibit significant differences between the genotypes (two-way ANOVA, P = 0.94). The effect of THC in b-arrestin2 + / + mice did not exceed 25% MPE at any time and was not significantly greater (P = 0.82) than the effect of vehicle (Fig. 4, right panel) . In b-arrestin2 -/mice, however, THC produced significantly greater effects than vehicle (P < 0.02) from 60-120 min. As in the tail flick and rectal temperature assays above, the effect of THC in the hot plate test was significantly greater in b-arrestin2 -/than in + / + mice (two-way ANOVA: Interaction P = 0.53, genotype P < 0.01, time P < 0.05, Bonferroni's posttest P < 0.05 at 90 min).
CB 1 receptor density in brain membrane homogenates Saturation analysis with the CB 1 receptor-selective antagonist, [ 3 H]SR141716A, was conducted in cerebellar membranes (Fig. 5) . B max values were 4.1 ± 0.3 pmol/mg versus 4.1 ± 0.4 pmol/mg and K d values were 1.3 ± 0.1 versus 1.2 ± 0.1 nmol/l, respectively. In cortex and hippocampus membranes, complete saturation analysis was not carried out, but the amount of specific binding obtained with 1.0 nmol/l [ 3 H]SR141716A was determined in b-arrestin2 + / + and -/mice (Fig. 5, inset) . In cortex membranes, [ 3 H]SR141716A exhibited 1.6 ± 0.3 and 1.8 ± 0.2 pmol/mg of binding, respectively. In hippocampal membranes, [ 3 H]SR141716A bound 1.7 ± 0.3 and 1.9 ± 0.2 pmol/mg, respectively. In cerebellar membranes analyzed in the same way (the amount of binding at 1.0 nmol/l [ 3 H]SR141716A) there was 2.5 ± 0.5 and 2.1 ± 0.4 pmol/mg of binding. None of the three brain areas investigated showed significant differences in the amount of CB 1 receptor binding between b-arrestin2 + / + and -/mice (P > 0.05 by Student's t-test for each brain region).
Agonist-stimulated [ 35 S]GTPgS binding to wild-type mouse cerebellar membranes was measured for each of the agonists used in the in-vivo experiments in this study. This was carried out to confirm the relative efficacy for each agonist to be possible to classify each as a full or partial agonist at the CB 1 receptor. Results (Table 2) indicated that CP55940 and methanandamide were both full agonists, exhibiting E max values of about 135% stimulation over basal [ 35 S]GTPgS binding values.
Though both full agonists, the potencies of CP55940 and methanandamide varied over a 100-fold range with logEC 50 values of -7.7 and -5.7, respectively. The remaining three agonists exhibited similar concentrationeffect curves. THC, JWH-073, and O-1812 were all partial agonists and exhibited E max values between 53 and 72% stimulation (between 40 and 52% of the values exhibited by the full agonists). JWH-073 and O-1812 had potencies similar to that of THC (log EC 50 value -6.6) with logEC 50 values of -6.3 and -6.2, respectively ( Table 2 ).
Discussion
The effect of deletion of b-arrestin2 on basal tail withdrawal latencies at lower water bath temperatures was nearly identical to that noted by Bohn et al. (2000) , and indicates a role for b-arrestin2 in the responsiveness of pain pathways in the central nervous system. As these data were collected in the absence of a drug treatment, there is little evidence for the receptor system(s) or other biochemical mechanism involved in this effect. GPCRs are, however, implicated as they are the targets of regulation by b-arrestin2.
This is the first study to demonstrate the effects of cannabinoid receptor agonists in transgenic b-arrest-in2 -/mice, and the effects of only a few other substances in these mice have earlier been published (Bohn et al., , 2000 (Bohn et al., , 2002 (Bohn et al., , 2003 (Bohn et al., , 2004 Beaulieu et al., 2005; Bouxsein et al., 2005; Ferrari et al., 2005; Pi et al., 2005; Schmid et al., 2008) . In the earlier studies by Bohn et al. (1999 Bohn et al. ( , 2000 , it was noted that morphine exhibited enhanced activity in b-arrestin2 -/compared with b-arrestin2 + / + mice. In this study, CP55940 was assayed first at 1.0 mg/kg, and no differences between b-arrestin2 + / + and -/mice were observed. As this dose produce nearly maximal activity in the antinociception assay, it was hypothesized that the reason for the lack of difference between the genotypes was because of a ceiling effect; it would not be possible to observe a greater effect in the b-arrestin2 -/mice, as the effect in the + / + mice was already near the maximum possible effect. Thus, a lower dose of CP55940 (0.3 mg/kg) was subsequently assayed to observe the effects at a less than maximally effective dose. The effects at this dose were also found to be unaffected by deletion of b-arrestin2.
Next, the effects of the naturally occurring cannabinoid agonist, THC, were found to be enhanced in the absence of b-arrestin2, as seen for morphine (Bohn et al., , 2000 (Bohn et al., , 2003 (Bohn et al., , 2004 Raehal et al. 2005 Cannabinoids in beta-arrestin2 -/ -mice Breivogel et al. 305 effects in the -/mice (100% MPE, 90% MPE and 61C, respectively).
As CP55940 was known to be a full agonist and THC a partial agonist at CB 1 receptors in brain membranes (Table 2) (Breivogel et al., 2001) , it was hypothesized that b-arrestin2 deletion affected sensitivity to cannabinoid receptor partial agonists, but not full agonists. To test this hypothesis, one other full agonist, methanandamide, and two other partial agonists with efficacy and potency similar to THC, JWH-073, and O-1812, were assayed. The relative efficacy and thus identification of each of these agonists as full or partial was confirmed using the in-vitro [ 35 S]GTPgS binding assay in this study ( Table 2 ). The doses of each agonist used for the in-vivo assays were chosen based on earlier published ED 50 values for the same antinociception and hypothermia assays used in this study. The effects of these agonists, CP55940 (Compton et al., 1993) , THC (Wiley et al., 1998) , methanandamide (Abadji et al., 1994) , O-1812 , and JWH-073 (Wiley et al., 1998) on body temperature and latency to tail withdrawal were similar to what has been earlier observed in wild-type mice.
Though the levels of in-vivo activity varied somewhat between the agonists, each agonist produced significant hypothermia, and all but one produced significant antinociception at the doses administered. If the activity of any of these agonists had been enhanced by deletion of b-arrestin2, it is reasonable to expect that this effect would be observable at these doses. None of the data for any of the agonists (other than THC), however, showed a difference between b-arrestin2 + / + and -/mice.
The finding that the activity of THC was selectively increased by deletion of b-arrestin2 paralleled the findings of Bohn et al. (2004) where only the effects of morphine, or its derivative heroin, were enhanced in b-arrestin2 -/mice. Interestingly, THC and morphine are partial agonist for G-protein activation at CB 1 (Sim et al., 1996) or m (Selley et al., 1997) receptors, respectively, and each is a plant-derived exogenous ligand for its respective receptor. It is, however, clear from this study that partial agonist activity alone is not responsible for this selectivity, as neither of the other two partial CB 1 receptor agonists exhibited this effect.
To investigate whether the effect of deletion of b-arrestin2 on basal latency to tail withdrawal at 501C or the in-vivo effects of THC might be based on differences in CB 1 receptor density, the CB 1 -selective antagonist [ 3 H]SR141716A was used to measure the total number of CB 1 receptors in three different brain regions. Cerebellum, cortex, and hippocampus represent three brain regions that express similarly high levels of CB 1 receptors (Herkenham et al., 1990) , and cortex and hippocampus express relatively high levels of b-arrestin2, while cerebellum displays lower levels (Gurevich et al., 2002 (Gurevich et al., , 2004 . No differences were observed between b-arrestin2 + / + and -/mouse brain in cannabinoid CB 1 receptor density in any brain region examined; analogous to what was found earlier for the m opioid receptor . This is not surprising, as a difference in overall CB 1 receptor density would likely affect the activity of all the agonists, or at least all of the partial agonists, and not just THC.
The main finding of this study is that in-vivo effects of THC were selectively influenced by the absence of b-arrestin2. The reason, however, for the agonist-selective effects of b-arrestin2 is clearly not because of the low efficacy of THC, as the differences between b-arrestin2 + / + and -/mice were not seen with either of the two other agonists with similarly low efficacy (O-1812 and JWH-073). A likely hypothesis for this selectivity is that THC is able to activate CB 1 receptors in a manner that recruits only b-arrestin2 to interact with it, whereas the other agonists are able to recruit either b-arrestin1 or b-arrestin2 to interact with CB 1 receptors, analogous to what was observed for m receptor agonists (Bohn et al., 2004) . The fact that the activity of THC and morphinebased agonists were selectively affected by deletion of b-arrestin2 suggests that agonist-selective involvement of b-arrestin2 in the regulation of GPCRs may be a common phenomenon.
The biochemical mechanism by which even morphine exerts this agonist-specific effect has not been investigated. Some possibilities include recruitment of specific GRKs subtypes to phosphorylate GPCRs, induction of selective patterns of phosphorylation of GPCRs by GRKs (that affect selective binding of b-arrestin subtypes), or selective coupling of b-arrestins to GPCRs (even in the presence of identical phosphorylation).
The fact that the activity of THC was affected indicates an important role for b-arrestin2 in the context of the recreational use/abuse of marijuana or the medicinal use of Marinol, as THC is the main active component of each of these. Perhaps some future therapy will take advantage of the selective regulation of the activity of THC (and/or morphine) by modulating the activity of b-arrestins.
